文献速递临床试验与 GCP

腹腔镜远端胃切除术(D2+CME)对比传统D2淋巴结清扫治疗局部进展期胃腺癌的前瞻性随机对照试验:研究方案

Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-08-09

本研究为单中心前瞻性随机对照试验,纳入336例局部进展期胃腺癌患者,随机接受腹腔镜远端胃切除术D2+CME或传统D2淋巴结清扫,主要终点为3年无病生存率,旨在验证D2+CME能否改善肿瘤学疗效。

要点

  • D2+CME在理论上可完整切除胃系膜近端背侧段,短期手术结局更优。
  • 该试验主要终点为3年无病生存率,次要终点包括总生存、复发模式等。
  • 研究结果可能为局部进展期胃癌手术方式优化提供高级别证据。

核心结论

  • D2+CME的肿瘤学治疗效果尚未被证实,本试验旨在评估其能否改善局部进展期胃腺癌患者的预后。

研究设计与样本

  • 单中心、前瞻性、平行组随机对照试验,在中国武汉同济医院开展,共纳入336例符合标准的局部进展期胃腺癌患者。

关键数值与推荐

  • 纳入标准包括:病理证实腺癌;年龄18至75岁;术前评估cT2-4、N0-3、M0;预计可通过腹腔镜远端胃切除术达到根治性切除;无其他癌症、化疗或放疗史;无上腹部手术史;围手术期ASA分级I、II或III级。
  • 主要终点为3年无病生存率;次要终点包括总生存率、复发模式、死亡率、并发症率、术后恢复进程及其他参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although radical gastrectomy with D2 lymph node dissection has become the standard surgical approach for locally advanced gastric cancer, patients still have a poor prognosis after operation. Previously, we proposed laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision [D2 + CME]) as an optimized surgical procedure for locally advanced gastric cancer. By dissection along the boundary of the mesogastrium, D2 + CME resected proximal segments of the dorsal mesogastrium completely with less blood loss, and it improved the short-term surgical outcome. However, the oncologic therapeutic effect of D2 + CME has not yet been confirmed. METHODS/DESIGN: A single-center, prospective, parallel-group, randomized controlled trial of laparoscopic distal gastrectomy with D2 + CME versus conventional D2 was conducted for patients with locally advanced gastric cancer at Tongji Hospital, Wuhan, China. In total, 336 patients who met the following eligibly criteria were included and were randomized to receive either the D2 + CME or D2 procedure: (1) pathologically proven adenocarcinoma; (2) 18 to 75 years old; cT2-4, N0-3, M0 at preoperative evaluation; (3) expected curative resection via laparoscopic distal gastrectomy; (4) no history of other cancer, chemotherapy, or radiotherapy; (5) no history of upper abdominal operation; and (6) perioperative American Society of Anesthesiologists class I, II, or III. The primary endpoint is 3 years of disease-free survival. The secondary endpoints are overall survival, recurrence pattern, mortality, morbidity, postoperative recovery course, and other parameters. DISCUSSION: Previous studies have demonstrated the safety and feasibility of D2 + CME for locally advanced gastric cancer; however, there is still a lack of evidence to support its therapeutic effect. Thus, we performed this randomized trial to investigate whether D2 + CME can improve oncologic outcomes of patients with locally advanced gastric cancer. The findings from this trial may potentially optimize the surgical procedure and may improve the prognosis of patients with locally advanced gastric cancer. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01978444 . Registered on October 31, 2013.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Shen J, Cao B, Wang Y, et al. Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial. Trials. 2018. PMID: 30092843. doi:10.1186/s13063-018-2790-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。